📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Cell Pathways

1.1 - Company Overview

Cell Pathways Logo

Cell Pathways

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of small molecule-based drugs for cancer treatment leveraging an apoptosis technology platform, which can be used with other chemotherapy drugs, and of kits and methods for detection and quantification, including PCR ED ELISA kits for DIG-labeled PCR products, Endothelin-1 ELISA kits for multiple species, and combined PCR-ELISA nucleic acid detection.

Products and services

  • Development & Evaluation of PCR and Elisa kit: Creates a method that combines ELISA and PCR to enable sensitive, rapid nucleic acid detection in one process, hybrid-assay
  • Human endotoxin (ET) ELISA Kit: Quantifies Endothelin-1 across human, bovine, porcine, dog, rat, mouse serum, plasma, urine, or culture medium via colorimetric microplate reader, multi-species
  • PCR ED Elisa Kit: Enables semi-quantitative detection of digoxigenin (DIG)-labelled PCR products and supports up to 192 detection reactions per kit, semi-quantitative

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Cell Pathways

Step Pharma Logo

Step Pharma

HQ: France Website
  • Description: Provider of CTPS1 inhibition therapies, developing STP938, an orally bioavailable CTPS1 inhibitor in clinical development for treating blood cancers and potentially solid tumors. The approach targets the CTPS1 enzyme to inhibit a key step in nucleotide synthesis to treat various cancers.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Step Pharma company profile →
CASI Pharmaceuticals Logo

CASI Pharmaceuticals

HQ: United States Website
  • Description: Provider of business development aimed at building a pipeline through mutually beneficial transactions.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full CASI Pharmaceuticals company profile →
Somatex Logo

Somatex

HQ: Germany Website
  • Description: Provider of medical devices, located in Berlin.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Somatex company profile →
Noviga Research Logo

Noviga Research

HQ: Sweden Website
  • Description: Provider of research and development of small molecules aimed at new, more effective cancer treatment.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Noviga Research company profile →
Rain Oncology Logo

Rain Oncology

HQ: United States Website
  • Description: Provider of precision oncology therapies targeting oncogenic drivers, developing milademetan, an oral small molecule inhibitor of the p53-MDM2 complex for various cancers. Clinical programs include MANTRA (Phase 3 in dedifferentiated liposarcoma), MANTRA-2 (Phase 2 in TP53 wildtype/MDM2-amplified solid tumors), and MANTRA-4 (Phase 1/2 with atezolizumab in CDKN2A loss, TP53 wildtype tumors).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Rain Oncology company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Cell Pathways

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Cell Pathways

2.2 - Growth funds investing in similar companies to Cell Pathways

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Cell Pathways

4.2 - Public trading comparable groups for Cell Pathways

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Cell Pathways

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Cell Pathways

What does Cell Pathways do?

Cell Pathways is a provider of small molecule-based drugs for cancer treatment leveraging an apoptosis technology platform, which can be used with other chemotherapy drugs, and of kits and methods for detection and quantification, including PCR ED ELISA kits for DIG-labeled PCR products, Endothelin-1 ELISA kits for multiple species, and combined PCR-ELISA nucleic acid detection.

Who are Cell Pathways's competitors?

Cell Pathways's competitors and similar companies include Step Pharma, CASI Pharmaceuticals, Somatex, Noviga Research, and Rain Oncology.

Where is Cell Pathways headquartered?

Cell Pathways is headquartered in United States.

How many employees does Cell Pathways have?

Cell Pathways has 1,000 employees 🔒.

When was Cell Pathways founded?

Cell Pathways was founded in 2010 🔒.

What sector and industry vertical is Cell Pathways in?

Cell Pathways is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Cell Pathways

Who are the top strategic acquirers in Cell Pathways's sector and industry

Top strategic M&A buyers and acquirers in Cell Pathways's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Cell Pathways?

Top strategic M&A buyers groups and sectors for Cell Pathways include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Cell Pathways's sector and industry vertical

Which are the top PE firms investing in Cell Pathways's sector and industry vertical?

Top PE firms investing in Cell Pathways's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Cell Pathways's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Cell Pathways's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Cell Pathways's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Cell Pathways include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Cell Pathways's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Cell Pathways?

The key public trading comparables and valuation benchmarks for Cell Pathways include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Cell Pathways for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Cell Pathways with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Cell Pathways's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Cell Pathways with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Cell Pathways's' sector and industry vertical?

Access recent funding rounds and capital raises in Cell Pathways's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Cell Pathways